RxDoctor Payments Data

Linda Melendez Torres, MD

General Practice · Orlando, FLNPI 1316933708

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 81 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$373
  • AbbVie$295
  • AstraZeneca$271
  • GSK$141
  • Amgen$109
  • Johnson & Johnson$84
  • plus $288 from 9 others

What the payments were for

  • Food & beverage$1,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,562 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$130,439
Medicare patients
270
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$92,951
OzempicSemaglutide32$49,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$46,271
XareltoRivaroxaban28$39,727
TrulicityDulaglutide25$39,192
JardianceEmpagliflozin20$33,587
MounjaroTirzepatide19$21,689
GemtesaVibegron18$17,736
JanuviaSitagliptin Phosphate12$15,256
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$8,995
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$8,775
Breo ElliptaFluticasone/Vilanterol17$7,314
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,943
Duloxetine Hcl98$4,281
Rosuvastatin Calcium383$4,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$43$60,88144 claims
GSKTrelegy Ellipta, Breo Ellipta$141$53,58470 claims
Novo NordiskOzempic$373$49,40132 claims
Johnson & JohnsonXarelto$84$39,72728 claims
Boehringer IngelheimJardiance$12$33,58720 claims
AstraZenecaSymbicort$271$3,54012 claims
AbbVieSynthroid$295$3,41448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →